Biogen’s science & manufacturing expertise enables production of biosimilars of advanced biologics

Biogen believes biosimilars are central to safeguarding future healthcare innovation. Biosimilars can alleviate some of the burden on healthcare systems by offering cost savings and promoting earlier and sustainable access to therapies. Biosimilars can also expand options for patients and physicians to meet individual needs. Biogen has the expertise to manufacture and reliably supply biosimilars. 



Biosimilars are medicines that are highly similar to currently available biologic therapies, known as “reference medicines.” Having successfully delivered complex biologics for approximately 40 years, Biogen is one of only a handful of companies with the manufacturing capabilities and deep scientific expertise needed to produce biosimilars of advanced biologics.



Biogen’s portfolio of biosimilars medicines currently spans a number of indications across two distinct therapy areas; Ophthalmology and Immunology (also described as inflammatory disease).



Our portfolio (existing & pipeline) includes anti-VEGF (vascular endothelial growth factor) therapies, which  are marketed in the US, and in future will be marketed in the European Union, as well as other major markets worldwide including Canada, Japan and Australia.

Anti-VEGF therapies treat retinal vascular disorders, which are a leading cause of blindness.

These include: neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular oedema (DME); proliferative diabetic retinopathy (PDR); visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); visual impairment due to choroidal neovascularisation (CNV).

These therapies are biosimilars, referencing currently-available biologic products. By bringing biosimilars to a new therapeutic area, we are expanding treatment options with the goal of sustainably advancing broad, timely access to care for patients in need.

By applying our heritage of scientific innovation to clear medical needs, Biogen hopes to make a meaningful difference to the lives of the many patients we serve.



Our portfolio of anti-TNF therapies is marketed in the European Union, where Biogen is a leading provider of these medicines.

Anti-TNF treatments reduce inflammation and may prevent disease progression by targeting an inflammation-causing substance called Tumor Necrosis Factor (or “TNF”).

TNF inhibitors are used to treat inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), ankylosing spondylitis, and psoriasis.

There are an estimated 30 million patients in Europe today who are directly affected by these inflammatory conditions.  Biosimilar therapies have the potential to significantly and sustainably expand patient access to life-changing biological medicines.



At Biogen, our goal is to provide healthcare professionals with the information needed to support their clinical practice. 

The below websites have been created for healthcare professionals based in the EU. They outline important information on our products, key clinical data, supporting materials and other valuable resources. 

Visit the Benepali site

Visit the Imraldi site 

Visit the Flixabi site

For healthcare professionals based in the US:

Visit the Byooviz site

If you are a patient and would like to learn more about biosimilar product availability in countries in the EU, please contact your healthcare provider, or visit your local Biogen affiliate website.



Biogen currently serves 247,000 patients affected by Immune Medicated Inflammatory Diseases (IMIDs) across Europe - in addition to a large network of clinicians. Through our educational and digital initiatives, we aim to provide healthcare professionals with meaningful clinical education to help them in their clinical practice.

The Biosimilars Medical Academy is an educational platform designed by medical professionals to provide high quality medical education. The Academy brings you exclusive content on biological treatments and educational resources for selected therapy areas, using engaging content developed with internationally renowned Key Medical Experts (KMEs).

If you are a healthcare professional based in the EU, click here to access the Biosimilars Medical Academy.

If you are a healthcare professional based in the United States, click here to access the Biosimilars Medical Academy.